3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
3
Unknown
1
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Interventions
lutetium Lu 177 dotatate
4
lanreotide
3
(177)Lu-DOTA-EB-TATE
3
Positron Emission Tomography Computed Tomography
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Metformin
2
Fluorodeoxyglucose F18
2
Everolimus
2
Capecitabine
2
Biopsy
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
sintilimab
1
recombinant interferon alpha 2b-like protein
1
gallium Ga 68 dotatate
1
copper dotatate CU-64
1
cabozantinib
1
anlotinib
1
amino-acid, glucose, and electrolyte solution
1
Yttrium-90
1
Tomography, Emission-Computed, Single-Photon
1
Temozolomide
1
Surgical Procedures, Operative
1
Somatostatin
1
Plastic Surgery Procedures
1
Phlebotomy
1
Nivolumab
1
Needles
1
Magnetic Resonance Spectroscopy
1
Lysine
1
Lutetium-177
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Neuroendocrine Tumors
×
90Y-octreotide, DOTA-Tyr(3)-
×
Clear all
NCT04790708
2021-03-10
FENET-2016
University Hospital of Ferrara
Phase NA
Unknown
250 enrolled